Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF

Thorax

Volumn 71, Issue 8, 2016, Pages 701-711

  Mercer, Paul F ^a   Woodcock, Hannah V ^a   Eley, Jessica D ^a   Platé, Manuela ^a   Sulikowski, Michal G ^a   Durrenberger, Pascal F ^a   Franklin, Linda ^a   Nanthakumar, Carmel B ^b   Man, Yim ^b   Genovese, Federica ^c   McAnulty, Robin J ^a   Yang, Shuying ^b   Maher, Toby M ^d   Nicholson, Andrew G ^d   Blanchard, Andy D ^b   Marshall, Richard P ^b   Lukey, Pauline T ^b   Chambers, Rachel C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c NORDIC BIOSCIENCE A S   (Denmark)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN; OMIPALISIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; 2,4-DIFLUORO-N-(2-(METHYLOXY)-5-(4-(4-PYRIDAZINYL)-6-QUINOLINYL)-3-PYRIDINYL)BENZENESULFONAMIDE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BIOSENSOR; CELL ASSAY; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EVIDENCE BASED PRACTICE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FIBROBLAST; LUNG LAVAGE; LUNG PARENCHYMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); FIBROBLAST; IDIOPATHIC PULMONARY FIBROSIS; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; FIBROBLASTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; QUINOLINES; SIGNAL TRANSDUCTION; SULFONAMIDES; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84964907177     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207429     Document Type: Article

References (39)

1. Lee AS, Mira-Avendano I, Ryu JH, et al. The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med 2014;108:955-67.
2. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
4. Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 2011;163:141-72.
5. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012;11:790-811.
6. Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008;177:56-65.
7. Parker MW, Rossi D, Peterson M, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 2014;124:1622-35.
8. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 2005;11:431-7.
9. Rabinovich EI, Kapetanaki MG, Steinfeld I, et al. Global methylation patterns in idiopathic pulmonary fibrosis. PLoS ONE 2012;7:e33770.
10. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am J Respir Crit Care Med 2014;189:1161-72.
11. Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 2013;22:265-72.
12. Groves AM, Win T, Screaton NJ, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med 2009;50:538-45.
13. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:329-41.
14. Conte E, Gili E, Fruciano M, et al. PI3K p110? overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition. Lab Invest 2013;93:566-76.
15. Horowitz JC, Lee DY, Waghray M, et al. Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J Biol Chem 2004;279:1359-67.
16. Kavanaugh WM, Klippel A, Escobedo JA, et al. Modification of the 85-kilodalton subunit of phosphatidylinositol-3 kinase in platelet-derived growth factor-stimulated cells. Mol Cell Biol 1992;12:3415-24.
17. White ES, Atrasz RG, Hu B, et al. Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med 2006;173:112-21.
18. Xia H, Diebold D, Nho R, et al. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J Exp Med 2008;205:1659-72.
19. Conte E, Fruciano M, Fagone E, et al. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms. PLoS ONE 2011;6:e24663.
20. Le Cras TD, Korfhagen TR, Davidson C, et al. Inhibition of PI3K by PX-866 prevents transforming growth factor-Alpha-induced pulmonary fibrosis. Am J Pathol 2010;176:679-86.
21. Knight SD, Adams ND, Burgess JL, et al. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med Chem Lett 2010;1:39-43.
22. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
23. Keerthisingam CB, Jenkins RG, Harrison NK, et al. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001;158: 1411-22.
24. Crowley C, Klanrit P, Butler CR, et al. Surface modification of a POSS-nanocomposite material to enhance cellular integration of a synthetic bioscaffold. Biomaterials 2016;83:283-93.
25. Leeming DJ, Larsen DV, Zhang C, et al. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)-Assessment of corresponding epitopes. Clin Biochem 2010;43: 1249-56.
26. Chambers RC, Laurent GJ, Westergren-Thorsson G. Cadmium inhibits proteoglycan and procollagen production by cultured human lung fibroblasts. Am J Respir Cell Mol Biol 1998;19:498-506.
27. Chen CZ, Peng YX, Wang ZB, et al. The Scar-in-A-Jar: studying potential antifibrotic compounds from the epigenetic to extracellular level in a single well. Br J Pharmacol 2009;158:1196-209.
28. Hong M, Wilkes MC, Penheiter SG, et al. Non-Smad transforming growth factor-β signaling regulated by focal adhesion kinase binding the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 2011;286:17841-50.
29. Bozulic L, Hemmings BA. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 2009;21:256-61.
30. Islam MR, Jones SJ, Macluskey M, et al. Is there a pAkt between VEGF and oral cancer cell migration? Cell Signal 2014;26:1294-302.
31. Vincent EE, Elder DJ, Thomas EC, et al. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer 2011;104:1755-61.
32. Foukas LC, Berenjeno IM, Gray A, et al. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci USA 2010;107:11381-6.
33. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014;13:140-56.
34. Gibbons MA, MacKinnon AC, Ramachandran P, et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med 2011;184:569-81.
35. Murray LA, Rosada R, Moreira AP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS ONE 2010;5:e9683.
36. Prasse A, Pechkovsky DV, Toews GB, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006;173:781-92.
37. Stahl M, Schupp J, Jäger B, et al. Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activation. PLoS ONE 2013;8:e81382.
38. Marone R, Cmiljanovic V, Giese B, et al. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008;1784:159-85.
39. Anderton MJ, Mellor HR, Bell A, et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol 2011;39:916-24.